Condition: Nasopharyngeal Carcinoma · Sponsor: Sun Yat-sen University
This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
This description comes directly from the study's public registry record.
Jingjing Miao, PhD · +8613631355201 · miaojj@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Peking University Third Hospital | Beijing, China | Recruiting |
| Sichuan Cancer Hospital | Chengdu, China | Not Yet Recruiting |
| Fujian Province Cancer Hospital | Fuzhou, China | Not Yet Recruiting |
| Guizhou Cancer Hospital | Guiyang, China | Not Yet Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, China | Recruiting |
| Jiangxi Cancer Hospital | Nanchang, China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University | Nanning, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Not Yet Recruiting |
| Zhongnan Hospital of Wuhan University | Wuhan, China | Recruiting |
| Xijing Hospital | Xi'an, China | Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05340491